ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0403 • ACR Convergence 2023

    Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis

    Courtney Loecker1, Bryant England2, Punyasha Roul2, Namrata Singh3, Kaleb Michaud2, Lani Zimmerman4, Myra Schmaderer4, Grant Cannon5, Ted R Mikuls6, Gary Kunkel7, Ariela Orkaby8, Joshua Baker9 and K Wysham10, 1University of Nebraska Medical Center;VA Nebraska-Western Iowa Health Care System, Lincoln, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Washington, Bellevue, WA, 4University of Nebraska Medical Center, Lincoln, NE, 5University of Utah and Salt Lake City VA, Salt Lake City, UT, 6Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, 7VA Salt Lake City & University of Utah, Salt Lake City, UT, 8Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; VA Geriatric Research Education and Clinical Center, Boston, MA, 9University of Pennsylvania, Philadelphia, PA, 10VA Puget Sound/University of Washington, Seattle, WA

    Background/Purpose: Frailty, defined as an increased vulnerability to stressors and adverse health outcomes, is an emerging concept in RA. Active RA disease gives rise to…
  • Abstract Number: 0382 • ACR Convergence 2023

    Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation

    Irini Flouri1, Antonios Bertsias2, Argyro Repa2, Nestor Avgoustidis2, Eleni Kalogiannaki2, Sofia Pitsigavdaki3, George Bertsias4 and Prodromos Sidiropoulos4, 1University of Crete Medical School, Heraklion, Greece, 2Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, 3Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, 4Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece

    Background/Purpose: Early detection of difficult to treat (D2T) RA patients as well as better characterization of their long-term course represent unresolved issues. Herein we aimed…
  • Abstract Number: 0442 • ACR Convergence 2023

    Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices

    Elliot Rosenstein1, Michael Weinblatt2, Annelie Everts-van der Wind3, John Conklin3 and Thierry Dervieux3, 1Institute for Rheumatic & Autoimmune Diseases--Atlantic Health System, Far Hills, NJ, 2Harvard Medical School, Waban, MA, 3Prometheus Laboratories, San Diego, CA

    Background/Purpose: Infliximab (IFX) has become a mainstay of treatment of many different immune-mediated inflammatory diseases. With the wide range of IFX dosing and dosing intervals,…
  • Abstract Number: 0430 • ACR Convergence 2023

    A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis

    Maria Lopez-Lasanta1, Helena Borrell1, Meritxell Salles Lizarzaburu2, Virginia Ruiz-Esquide3, Daniel Roig4, Annika Nack5, Carolina Pérez6, Julia Bernardez7, Andrea García8, Joana Rovira9, Andrea Cuervo10, Marta Valls11, Carmen Garcia12, Sonia Minguez13, Rosa Morla14, Paula Estrada4, Melania Martinez15, Conxita Pitarch16, Noemi Busquets17, Hye Park18, Jose A Gomez-Puerta19, Susana Holgado20, Nuria Montala21, Raimon Sanmarti3, Lourdes Mateo20, Cesar Diaz22, Hector Corominas23 and Georgina Salvador7, 1Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, 2C. H. de Manresa - Fundació Althaia, Barcelona, Spain, 3Hospital Clinic, Rheumatology, Barcelona, Spain, 4Hospital Moisses Broggi, Rheumatology, Barcelona, Spain, 5Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 6Hospital del Mar-Parc de Salut Mar, Rheumatology, Barcelona, Spain, 7Hospital Mutua Terrassa, Rheumatology, Barcelona, Spain, 8Hospital Sant Pau-Dos de Maig, Rheumatology, Barcelona, Spain, 9Hospital de Mollet, Barcelona, Spain, 10Hospital Granollers, Rheumatology, Barcelona, Spain, 11Hospital Josep Trueta, Rheumatology, Girona, Spain, 12Hospital de Terrassa, Rheumatology, Barcelona, Spain, 13Fundació Althaia, Manresa, Spain, 14Hospital Clinic, Rheumatology, Barcelona, Barcelona, Spain, 15Hospital Germans Trias i Pujol, Rheumatology, Barcelona, Spain, 16Hospital Universitari de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain, 17HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, 18Hospital Universitari Sant Pau, Rheumatology, Barcelona, Spain, 19Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, 20Hospital Universitari Germans Trias i Pujol, Rheumatology, Barcelona, Spain, 21Hospital Santa Maria, Rheumatology, Lleida, Spain, 22Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 23Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain

    Background/Purpose: The Janus Kinase inhibitors (JAKi) drugs are approved for use in adults with moderate to severe rheumatoid arthritis (RA). Real-world studies are necessary as…
  • Abstract Number: 0815 • ACR Convergence 2023

    Intermittent Fasting Reduces Crystal-induced Inflammation

    Nghia Pham1, Twinu Wilson Chirayath2, Florence Castelli3, François Fenaille3, Anvi-Laetitia Nguyen3, François Brial4, Augustin Latourte4, Frédéric Lioté4, Pascal Richette5, Thomas Bardin6 and Hang Korng EA7, 1INSERM 1132, BIOSCAR, Lariboisière hospital, Paris, France, 2INSERM, Paris, France, 3Laboratoire d’études du métabolisme des médicaments UMS 28, CEA Saclay, Gif-sur-Yvette, France, 4INSERM 1132, BIOSCAR, Paris, France, 5Lariboisière Hospital, Paris, France, 6Université de Paris Cité, Paris, France, 7INSERM-BIOSCAR, Paris, France

    Background/Purpose: Inflammation induced by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals depends on interleukin (IL)-1β activated by the NLRP3 inflammasome. The inflammatory response can…
  • Abstract Number: 0461 • ACR Convergence 2023

    Self-esteem as a Determinant of Sexual Function in SLE Patients

    María Espinosa-León1, Daniela Marengo-Rodríguez2, Monserrat Ibarra-Velasco2, Ana Barrera-Vargas2 and Javier Merayo-Chalico3, 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, 3Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico

    Background/Purpose: Rheumatic diseases, and specifically SLE, present with greater sexual dysfunction than other chronic diseases. Sexual dysfunction (SxD) is multifactorial and comprises disease-related factors, psychological…
  • Abstract Number: 0459 • ACR Convergence 2023

    Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial

    Ronald van Vollenhoven1, Vibeke Strand2, Tsutomu Takeuchi3, Nilmo Chávez4, Pablo Mannucci Walter5, Attul Singhal6, Jerzy Swierkot7, Nasser Khan8, Xianwei Bu9, Yihan Li9, Sara Penn9, Heidi Camp9 and Jacob Aelion10, 1Amsterdam University Medical Centers, Amsterdam, Netherlands, 2Stanford University, Portola Valley, CA, 3Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 4Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala, 5Aprillus Asistencia e Investigación, Buenos Aires, Argentina, 6Southwest Rheumatology Research Group, Dallas, TX, 7Department of Rheumatology and Internal Medicine, Wrocław Medical Hospital, Wrocław, Poland, 8Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, 9AbbVie, Inc., North Chicago, IL, 10West Tennessee Research Institute, Jackson, TN

    Background/Purpose: To evaluate the efficacy and safety of upadacitinib (UPA) monotherapy vs MTX monotherapy over 5 yrs among MTX-naïve patients with moderately to severely active…
  • Abstract Number: 0817 • ACR Convergence 2023

    Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial)

    Bedru Abafita1, Ambrish Singh1, Dawn Aitken1, Steffany Moonaz2, Andrew J Palmer1, Leigh Blizzard1, Changhai Ding1, Stan Drummen1, Graeme Jones3, Kim Bennell4 and Benny Samuel Antony1, 1Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 2Department of Clinical and Health Services Research, Southern California University of Health Sciences, Whittier, CA, 3Menzies Institute for Medical Research, University of Tasmania, Melbourne, Australia, 4University of Melbourne, Melbourne, Australia

    Background/Purpose: There is uncertainty about the best type of exercise to optimise outcomes for people with knee osteoarthritis (OA). Strengthening exercise is commonly recommended. However,…
  • Abstract Number: 0349 • ACR Convergence 2023

    Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care

    Karen Carpio Astudillo1, Daniel clemente Garulo2, Juan Carlos Lopez-Robledillo3, Camille Bourgeois Avella4, Laura Trives Folguera4, Amparo López López1, Jose María Alvaro-Gracias4, Indalecio Monteagudo Sáez1 and Juan carlos Nieto-Gonzalez5, 1Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, 3Hospital Infantil Universitario Niño Jesús, Madrid, Spain, 4Hospital General Universitario Gregorio Marañon, Madrid, Spain, 5Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) are a group of heterogeneous arthritis with onset in childhood. According to previous studies, this patients experience an improvement of…
  • Abstract Number: 0468 • ACR Convergence 2023

    Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes

    Heejo Keum1, Bonnie Bermas2, Shivani Patel1, Benjamin Chong1 and Heidi Jacobe1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2UT Southwestern, Dallas, TX

    Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…
  • Abstract Number: 0470 • ACR Convergence 2023

    Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic

    Caroline Siegel1, Deanna Jannat-Khah1, Avi Mikhaylov1, Erika Abramson2, Nancy Pan1 and Lisa Sammaritano3, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Only one-third of reproductive-aged women with rheumatic disease (RD) are prescribed effective contraception, even if prescribed teratogenic medications (Talabi et al. Arthritis Care Res.…
  • Abstract Number: 0457 • ACR Convergence 2023

    Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival

    Deanna Jannat-Khah1, Jeffrey R Curtis2, Fenglong Xie3, Ashish Saxena4 and Anne Bass5, 1Hospital For Special Surgery, New York, NY, 2Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, 3University of Alabama at Birmingham, Birmingham, AL, 4Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: There is a dearth of knowledge around the safety of biologic disease modifying antirheumatic drugs (bDMARDS) in immune checkpoint inhibitor (ICI)-treated rheumatoid arthritis (RA)…
  • Abstract Number: 0478 • ACR Convergence 2023

    The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children

    Maria Grazia Lazzaroni1, Eleonora Pedretti1, Liala Moschetti1, Marzia Bendoni2, Lucrezia Visconti2, Anna Molinaro2, Cecilia Nalli3, Franco Franceschini3, Paolo Airò1, Jessica Galli2, Elisa Fazzi2, Angela Tincani4 and Laura Andreoli5, 1Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 2Unit of Child and Adolescent Neuropsychiatry, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 4Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, 5University of Brescia, Brescia, Italy

    Background/Purpose: The long-term neuropsychiatric (NP) outcome of children born to mothers affected by autoimmune diseases (AIDs) represents a controversial topic, with few studies1-3 reporting a…
  • Abstract Number: 0474 • ACR Convergence 2023

    Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample

    Karun Shrestha1, Prakriti Subedi1, Manoj Ghimire1, Sajana Poudel2, Kalpana Ghimire1, Sai Keerthi Parvatheneni1, Mrunalini Dandamudi1, Laura Pedraza1, Luisa Brito1 and Liliya Gandrabur3, 1Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY, 2Department of Internal Medicine, John H Stroger Jr Hospital of Cook County, Chicago, IL, 3SBH Health System, Forest Hills, NY

    Background/Purpose: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) & vasculitis are autoimmune rheumatic diseases (ARDs) with systemic involvement. Management of women with ARDs during pregnancy…
  • Abstract Number: 0479 • ACR Convergence 2023

    Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry

    Catherine Sims1, Christine Yeung2, Heather Tam3, Joyce Kullman4, Amanda Eudy5, Renee Borchin6, Cristina Burroughs6, Megan Clowse7 and Peter Merkel2, 1Duke University School of Medicine, Durham, NC, 2University of Pennsylvania, Philadelphia, PA, 3Vasculitis Patient Powered Research Network, Stanford, CA, 4Vasculitis Foundation, Kansas City, MO, 5Duke University, Raleigh, NC, 6University of South Florida, Tampa, FL, 7Duke University, Chapel Hill, NC

    Background/Purpose: There are limited data on the reproductive health and experiences of women with vasculitis. This study engaged women with vasculitis to understand their perspectives…
  • « Previous Page
  • 1
  • …
  • 224
  • 225
  • 226
  • 227
  • 228
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology